Exciting News, Pharmidex in Molecular Glues Meeting
March 21, 2025
We’re pleased to announce that
Janette Dalay Robertson, our Business Development Manager, and
Ian Knowles, our Head of Respiratory, will be attending the 2nd SMR Molecular Glues Meeting on Friday, 21st March 2025 at GSK, Stevenage.
This event is a fantastic opportunity to engage with fellow scientists, innovators, and industry leaders in the field of molecular glues.
Janette and Ian are eager to connect, share insights, and explore new collaborations to advance drug discovery and development.
If you’re attending, don’t hesitate to reach out – they would love to meet and discuss how
Pharmidex can support your research and development goals!
🔗 More about the event:
https://lnkd.in/d6yiTkUi
#Pharmidex #DrugDiscovery #MolecularGlues #Collaboration #Biotech #SMR2025
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩🔬 👨🔬 Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs. ✅ Human-relevant metabolism data ✅ Supports IND-enabling ®gulatory studies ✅ Ideal for metabolite profiling, DDI risk & toxicity assessment By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development. 📩 Contact us to see how 8HUM can support your project.
